Rituximab for idiopathic membranous nephropathy: who can benefit?

Piero Ruggenenti, Carlos Chiurchiu, Mauro Abbate, Annalisa Perna, Paolo Cravedi, Mario Bontempelli, Giuseppe Remuzzi

Research output: Contribution to journalArticle

Abstract

Rituximab effectively reduces proteinuria in patients with idiopathic membranous nephropathy (IMN), but response to treatment may vary from patient to patient. The association between baseline clinical, laboratory, and histology covariates and proteinuria reduction was evaluated retrospectively by multiple linear regression analysis at 3 mo after rituximab therapy in 14 patients with IMN with proteinuria > 3.5 g/24 h while on angiotensin-converting enzyme inhibition for at least 6 mo and no previous remissions. The association strength was expressed by standardized beta coefficients (SbetaC). Glomerular (SbetaC = 0.48, P = 0.049) and tubulointerstitial (TI) scores (SbetaC = 0.61, P = 0.003) predicted the outcome. Among glomerular and TI score components, tubular atrophy (SbetaC = 0.59, P = 0.003) and interstitial fibrosis (SbetaC = 0.60, P = 0.001) were significantly associated with 3-mo proteinuria. Urinary protein excretion decreased from 9.1 +/- 4.0 to 4.6 +/- 3.5 g/24 h (P <0.001) in eight patients with TI score 1.7 but did not change in six with a score > or = 1.7. Nine additional patients with IMN then were allocated prospectively to rituximab treatment on the basis of a TI score <1.7. Three-month proteinuria decreased in all patients from 8.9 +/- 5.3 to 4.9 +/- 3.9 g/24 h (P <0.001) and serum albumin increased from 2.2 +/- 0.6 to 2.8 +/- 0.5 mg/dl (P <0.01). Changes in serum albumin and cholesterol were inversely correlated (P <0.02, r = -0.44). Rituximab achieved CD20 and CD19 depletion in all patients. In patients with IMN and nephrotic proteinuria despite angiotensin-converting enzyme inhibition therapy, renal biopsy findings may help in predicting response to rituximab and defining selection criteria for randomized trials that aim to assess the risk/benefit profile of B cell target therapy as compared with aspecific immunosuppressants and/or conservative therapy alone.

Original languageEnglish
Pages (from-to)738-748
Number of pages11
JournalClinical Journal of the American Society of Nephrology
Volume1
Issue number4
DOIs
Publication statusPublished - Jul 2006

Fingerprint

Membranous Glomerulonephritis
Proteinuria
Peptidyl-Dipeptidase A
Serum Albumin
Enzyme Therapy
Rituximab
Immunosuppressive Agents
Cell- and Tissue-Based Therapy
Patient Selection
Atrophy
Linear Models
Histology
Fibrosis
B-Lymphocytes
Therapeutics
Cholesterol
Regression Analysis
Kidney
Biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rituximab for idiopathic membranous nephropathy : who can benefit? / Ruggenenti, Piero; Chiurchiu, Carlos; Abbate, Mauro; Perna, Annalisa; Cravedi, Paolo; Bontempelli, Mario; Remuzzi, Giuseppe.

In: Clinical Journal of the American Society of Nephrology, Vol. 1, No. 4, 07.2006, p. 738-748.

Research output: Contribution to journalArticle

Ruggenenti, Piero ; Chiurchiu, Carlos ; Abbate, Mauro ; Perna, Annalisa ; Cravedi, Paolo ; Bontempelli, Mario ; Remuzzi, Giuseppe. / Rituximab for idiopathic membranous nephropathy : who can benefit?. In: Clinical Journal of the American Society of Nephrology. 2006 ; Vol. 1, No. 4. pp. 738-748.
@article{016c7d4f4c1e4932ad7cab33d5324a1e,
title = "Rituximab for idiopathic membranous nephropathy: who can benefit?",
abstract = "Rituximab effectively reduces proteinuria in patients with idiopathic membranous nephropathy (IMN), but response to treatment may vary from patient to patient. The association between baseline clinical, laboratory, and histology covariates and proteinuria reduction was evaluated retrospectively by multiple linear regression analysis at 3 mo after rituximab therapy in 14 patients with IMN with proteinuria > 3.5 g/24 h while on angiotensin-converting enzyme inhibition for at least 6 mo and no previous remissions. The association strength was expressed by standardized beta coefficients (SbetaC). Glomerular (SbetaC = 0.48, P = 0.049) and tubulointerstitial (TI) scores (SbetaC = 0.61, P = 0.003) predicted the outcome. Among glomerular and TI score components, tubular atrophy (SbetaC = 0.59, P = 0.003) and interstitial fibrosis (SbetaC = 0.60, P = 0.001) were significantly associated with 3-mo proteinuria. Urinary protein excretion decreased from 9.1 +/- 4.0 to 4.6 +/- 3.5 g/24 h (P <0.001) in eight patients with TI score 1.7 but did not change in six with a score > or = 1.7. Nine additional patients with IMN then were allocated prospectively to rituximab treatment on the basis of a TI score <1.7. Three-month proteinuria decreased in all patients from 8.9 +/- 5.3 to 4.9 +/- 3.9 g/24 h (P <0.001) and serum albumin increased from 2.2 +/- 0.6 to 2.8 +/- 0.5 mg/dl (P <0.01). Changes in serum albumin and cholesterol were inversely correlated (P <0.02, r = -0.44). Rituximab achieved CD20 and CD19 depletion in all patients. In patients with IMN and nephrotic proteinuria despite angiotensin-converting enzyme inhibition therapy, renal biopsy findings may help in predicting response to rituximab and defining selection criteria for randomized trials that aim to assess the risk/benefit profile of B cell target therapy as compared with aspecific immunosuppressants and/or conservative therapy alone.",
author = "Piero Ruggenenti and Carlos Chiurchiu and Mauro Abbate and Annalisa Perna and Paolo Cravedi and Mario Bontempelli and Giuseppe Remuzzi",
year = "2006",
month = "7",
doi = "10.2215/CJN.01080905",
language = "English",
volume = "1",
pages = "738--748",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "by the American Society of Nephrology",
number = "4",

}

TY - JOUR

T1 - Rituximab for idiopathic membranous nephropathy

T2 - who can benefit?

AU - Ruggenenti, Piero

AU - Chiurchiu, Carlos

AU - Abbate, Mauro

AU - Perna, Annalisa

AU - Cravedi, Paolo

AU - Bontempelli, Mario

AU - Remuzzi, Giuseppe

PY - 2006/7

Y1 - 2006/7

N2 - Rituximab effectively reduces proteinuria in patients with idiopathic membranous nephropathy (IMN), but response to treatment may vary from patient to patient. The association between baseline clinical, laboratory, and histology covariates and proteinuria reduction was evaluated retrospectively by multiple linear regression analysis at 3 mo after rituximab therapy in 14 patients with IMN with proteinuria > 3.5 g/24 h while on angiotensin-converting enzyme inhibition for at least 6 mo and no previous remissions. The association strength was expressed by standardized beta coefficients (SbetaC). Glomerular (SbetaC = 0.48, P = 0.049) and tubulointerstitial (TI) scores (SbetaC = 0.61, P = 0.003) predicted the outcome. Among glomerular and TI score components, tubular atrophy (SbetaC = 0.59, P = 0.003) and interstitial fibrosis (SbetaC = 0.60, P = 0.001) were significantly associated with 3-mo proteinuria. Urinary protein excretion decreased from 9.1 +/- 4.0 to 4.6 +/- 3.5 g/24 h (P <0.001) in eight patients with TI score 1.7 but did not change in six with a score > or = 1.7. Nine additional patients with IMN then were allocated prospectively to rituximab treatment on the basis of a TI score <1.7. Three-month proteinuria decreased in all patients from 8.9 +/- 5.3 to 4.9 +/- 3.9 g/24 h (P <0.001) and serum albumin increased from 2.2 +/- 0.6 to 2.8 +/- 0.5 mg/dl (P <0.01). Changes in serum albumin and cholesterol were inversely correlated (P <0.02, r = -0.44). Rituximab achieved CD20 and CD19 depletion in all patients. In patients with IMN and nephrotic proteinuria despite angiotensin-converting enzyme inhibition therapy, renal biopsy findings may help in predicting response to rituximab and defining selection criteria for randomized trials that aim to assess the risk/benefit profile of B cell target therapy as compared with aspecific immunosuppressants and/or conservative therapy alone.

AB - Rituximab effectively reduces proteinuria in patients with idiopathic membranous nephropathy (IMN), but response to treatment may vary from patient to patient. The association between baseline clinical, laboratory, and histology covariates and proteinuria reduction was evaluated retrospectively by multiple linear regression analysis at 3 mo after rituximab therapy in 14 patients with IMN with proteinuria > 3.5 g/24 h while on angiotensin-converting enzyme inhibition for at least 6 mo and no previous remissions. The association strength was expressed by standardized beta coefficients (SbetaC). Glomerular (SbetaC = 0.48, P = 0.049) and tubulointerstitial (TI) scores (SbetaC = 0.61, P = 0.003) predicted the outcome. Among glomerular and TI score components, tubular atrophy (SbetaC = 0.59, P = 0.003) and interstitial fibrosis (SbetaC = 0.60, P = 0.001) were significantly associated with 3-mo proteinuria. Urinary protein excretion decreased from 9.1 +/- 4.0 to 4.6 +/- 3.5 g/24 h (P <0.001) in eight patients with TI score 1.7 but did not change in six with a score > or = 1.7. Nine additional patients with IMN then were allocated prospectively to rituximab treatment on the basis of a TI score <1.7. Three-month proteinuria decreased in all patients from 8.9 +/- 5.3 to 4.9 +/- 3.9 g/24 h (P <0.001) and serum albumin increased from 2.2 +/- 0.6 to 2.8 +/- 0.5 mg/dl (P <0.01). Changes in serum albumin and cholesterol were inversely correlated (P <0.02, r = -0.44). Rituximab achieved CD20 and CD19 depletion in all patients. In patients with IMN and nephrotic proteinuria despite angiotensin-converting enzyme inhibition therapy, renal biopsy findings may help in predicting response to rituximab and defining selection criteria for randomized trials that aim to assess the risk/benefit profile of B cell target therapy as compared with aspecific immunosuppressants and/or conservative therapy alone.

UR - http://www.scopus.com/inward/record.url?scp=34548443784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548443784&partnerID=8YFLogxK

U2 - 10.2215/CJN.01080905

DO - 10.2215/CJN.01080905

M3 - Article

C2 - 17699281

AN - SCOPUS:34548443784

VL - 1

SP - 738

EP - 748

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 4

ER -